Investors were provided with an insight into Nurix Therapeutics, Inc.'s (NASDAQ: NRIX) third quarter performance when the company revealed its earnings after the market has concluded for the day.
The results caught the attention of Wall Street, with earnings exceeding expectations but revenues falling short.
By the end of the quarter, the establishment's bottomline stood at loss of $0.67 per share, in contrast to loss of $0.68 per share exhibited in the matching quarter previous year.
Simultaneously, the revenues for the quarter measuring $12.59 million, declined 31.84 percent in contrast to the same quarter of previous year.
The figures gone beyond the analysts projected $0.72 loss per share, nevertheless failed to meet the estimated revenue of $15.76 million.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Q3 2024 | $-0.67 | +1.5% | 12.59 M | -31.8% |
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.71 | -57.8% | 12.09 M | -60.6% |
| Q1 2024 | $-0.76 | -1.3% | 16.59 M | +30.7% |
| Q4 2023 | $-0.77 | +11.5% | 15.16 M | +123.5% |
| Q3 2023 | $-0.68 | +24.4% | 18.47 M | +71.1% |
| Q2 2023 | $-0.45 | +55.4% | 30.68 M | +168.3% |
| *Growth on year-over-year basis | ||||
Nurix Therapeutics (NRIX) closed Friday's regular trading session at $23.63, indicating a 8.10 percent upturn. The stock fluctuated between $22.74 and $24.26 during the day, with a volume of 951.90 thousand shares.
